Nkarta Frames Lupus Plans, Cost Cuts Into A Pleasing Picture For Investors

With public biopharma stock valuations plunging during the past two years, cost-cutting plans to preserve cash on hand have become common until conditions are more favorable for fundraising through the sale of stock through public offerings. When a company finds itself in the position of having to prioritize some research and development programs over others while laying off a portion of its workforce, stock prices sometimes get a little boost as investors respond positively to executives responsibly managing their remaining resources, but often valuations take a hit.

Nkarta, Inc. investors had a remarkably positive reaction to the natural killer (NK) cell therapy developer’s strategic update on...